Genomic landscape of ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations

Cancer Discovery

Volumn 4, Issue 11, 2014, Pages 1342-1353

  Tirode, Franck ^a,b   Surdez, Didier ^a,b   Ma, Xiaotu ^c   Parker, Matthew ^c   Le Deley, Marie Cécile ^d   Bahrami, Armita ^c   Zhang, Zhaojie ^c   Lapouble, Eve ^e   Grossetete Lalami, Sandrine ^a,b   Rusch, Michael ^c   Reynaud, Stephanie ^e   Rio Frio, Thomas ^b   Hedlund, Erin ^c   Wu, Gang ^c   Chen, Xiang ^c   Pierron, Gaelle ^e   Oberlin, Odile ^d   Zaidi, Sakina ^a,b   Lemmon, Gordon ^c   Gupta, Pankaj ^c   Vadodaria, Bhavin ^c   Easton, John ^c   Gut, Marta ^f   Ding, L ^g,h   Mardis, Elaine R ^g,h   Wilson, Richard K ^g,h   Shurtleff, Sheila ^c   Laurence, Valerie ^e   Michon, Jean ^e   Marec Berard, Perrine ⁱ   Gut, Ivo ^f   Downing, James ^c   Dyer, Michael ^c,j   Zhang, Jinghui ^c   Delattre, Olivier ^a,b   more..

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e CENTRE HOSPITALIER   (France)

^f Parc Cientific de Barcelona   (Spain)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h USA   (United States)

ⁱ UNIVERSITÉ DE LYON   (France)

^j HOWARD HUGHES MEDICAL INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TRANSCRIPTION FACTOR EZH2; CELL NUCLEUS ANTIGEN; DNA; PROTEIN P53; STAG2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ARTICLE; BCOR GENE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; EWING SARCOMA; EWSR1 ETS GENE FUSION; FEMALE; GENE; GENE DELETION; GENE FUSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MLL2 GENE; MLL3 GENE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRDM9 GENE; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SETD2 GENE; SOMATIC MUTATION; STAG2 GENE; TP53 GENE; ZMYM3 GENE; BONE TUMOR; GENETICS; GENOMICS; MUTATION; PROGNOSIS; TUMOR CELL LINE;

ANTIGENS, NUCLEAR; BONE NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; GENOMICS; HUMANS; MUTATION; PROGNOSIS; SARCOMA, EWING; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908397914     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0622     Document Type: Article

References (50)

1. Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 2012; 7: 145-59.
2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-5.
3. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The Ewing’s sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993; 13: 7393-8.
4. Armengol G, Tarkkanen M, Virolainen M, Forus A, Valle J, Bohling T, et al. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 1997; 75: 1403-9.
5. Brisset S, Schleiermacher G, Peter M, Mairal A, Oberlin O, Delattre O, et al. CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases. Cancer Genet Cytogenet 2001; 130: 57-61.
6. Brownhill SC, Taylor C, Burchill SA. Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br J Cancer 2007; 96: 1914-23.
7. Hattinger CM, Potschger U, Tarkkanen M, Squire J, Zielenska M, Kiuru-Kuhlefelt S, et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 2002; 86: 1763-9.
8. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997; 15: 2225-32.
9. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K, et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 2012; 31: 1287-98.
10. Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S, et al. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer 2001; 32: 164-71.
11. Huang H-Y, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005; 23: 548-58.
12. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011; 333: 1039-43.
13. Wang J, Mullighan CG, Easton J, Roberts S, Heatley SL, Ma J, et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods 2011; 8: 652-4.
14. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012; 481: 329-34.
15. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-63.
16. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993; 12: 4481-7.
17. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979-93.
18. Remeseiro S, Cuadrado A, Losada A. Cohesin in development and disease. Dev Camb Engl 2013; 140: 3715-8.
19. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-8.
20. Huether R, Dong L, Chen X, Wu G, Parker M, Wei L, et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun 2014; 5: 3630.
21. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res 2012; 22: 1589-98.
22. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012; 483: 589-93.
23. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013; 45: 279-84.
24. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 2013; 45: 12-7.
25. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013; 24: 710-24.
26. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusionpositive and fusion-negative tumors. Cancer Discov 2014; 4: 216-31.
27. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488: 106-10.
28. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488: 43-8.
29. Jones DTW, Hutter B, Jager N, Korshunov A, Kool M, Warnatz H-J, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013; 45: 927-32.
30. Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, Pfaff E, J acob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482: 226-31.
31. Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 2014; 7: 104-12.
32. Mugneret F, Lizard S, Aurias A, Turc-Carel C. Chromosomes in Ewing’s sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). Cancer Genet Cytogenet 1988; 32: 239-45.
33. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Marquez M, Vazquez M, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 2013; 45: 1464-9.
34. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. W hole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013; 45: 1459-63.
35. Kon A, Shih L-Y, Minamino M, Sanada M, Shiraishi Y, Nagata Y, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013; 45: 1232-7.
36. Taylor CF, Platt FM, Hurst CD, Thygesen HH, Knowles MA. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet 2014; 23: 1964-74.
37. Xiao T, Wallace J, Felsenfeld G. Specific sites in the C terminus of CTCF interact with the SA2 subunit of the cohesin complex and are required for cohesin-dependent insulation activity. Mol Cell Biol 2011; 31: 2174-83.
38. Witcher M, Emerson BM. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 2009; 34: 271-84.
39. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 2001; 81: 803-14.
40. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 2000; 120: 91-8.
41. Patel N, Black J, Chen X, Marcondes AM, Grady WM, Lawlor ER, et al. DNA methylation and gene expression profiling of Ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation. Sarcoma 2012; 2012: 498472.
42. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677-92.
43. Berg T, Thoene S, Yap D, Wee T, Schoeler N, Rosten P, et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood 2014; 123: 3914-24.
44. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest 2012; 122: 3424-31.
45. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-506.
46. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet 2014; 10: e1004475.
47. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28: 3284-91.
48. Peter M, Gilbert E, Delattre O. A multiplex real-time pcr assay for the detection of gene fusions observed in solid tumors. Lab Invest 2001; 81: 905-12.
49. Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell 2013; 152: 1226-36.
50. Louis-Brennetot C, Coindre J-M, Ferreira C, Perot G, Terrier P, Aurias A. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors. Genes Chromosomes Cancer 2011; 50: 896-907.